Open AccessEFFECTS OF IMMUNOTHERAPY ON EXPERIMENTAL IMMUNODEFICIENCY-RELATED LYMPHOPROLIFERATIVE DISEASE1
Author(s) -
Parmjeet Randhawa,
Theresa L. Whiteside,
Adriana Zeevi,
Elaine M. Elder,
Abdul S. Rao,
Anthony J. Demetris,
Xue Weng,
Luis A. Valdivia,
Jorge Rakela,
Michael A. Nalesnik
Publication year - 1998
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199801270-00022
Subject(s) - in vivo , immunotherapy , medicine , immunology , lymphoproliferative response , lymphoproliferative disorders , lymphoproliferative disease , lymphocyte , immune system , lymphokine activated killer cell , lymphoblast , in vitro , t cell , cell culture , lymphoma , biology , peripheral blood mononuclear cell , interleukin 21 , biochemistry , microbiology and biotechnology , genetics
Human lymphokine-activated cells (LAK cells) and interferon alpha (IFN-alpha) have been used clinically in the therapy of posttransplant lymphoproliferative disease (PTLD). However, the efficacy of such therapy has not been extensively tested under controlled experimental conditions.